Gain Therapeutics‘ investigational STAR (small-molecule structurally targeted allosteric regulators) candidate lowered toxic amyloid-beta and tau protein levels, both hallmarks of Alzheimer’s disease, in a cellular model of the disease. Treatment with the STAR molecule enhanced the survival and boosted communication between nerve cells, the company announced. The results support the potential of STARs molecules for Alzheimer’s disease, after initial findings showed promise in Gain’s Parkinson’s disease program. “The new data corroborate similar results we have…
April 19, 2022April 19, 2022